RxDoctor Payments Data

Connie Nelson, APRN

Psychiatric/Mental Health · Lincoln, NENPI 1740829845

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 52.2% of the total. 2025 is the largest year on record at $1,216, more than ten times the $80 reported in 2021.

$3,509in general payments, 2019–2025

Across 211 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$706
  • Supernus Pharmaceuticals, Inc.$224
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$221
  • Alkermes, Inc.$181
  • Medline Industries LP$100
  • plus $245 from 5 others

What the payments were for

  • Food & beverage$3,509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,509 in reported general payments places this provider in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$5,196
Medicare patients
12
Services billed
59

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$15,378
FetzimaLevomilnacipran Hcl12$6,492
Hydroxyzine Hcl29$995
Gabapentin20$819
Topiramate19$572
Buspirone Hcl12$557
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$544
Methylphenidate ErMethylphenidate Hcl13$471
Lamotrigine23$469
Venlafaxine Hcl ErVenlafaxine Hcl34$409
Quetiapine Fumarate17$378
Aripiprazole13$316
Trazodone Hcl28$185
Sertraline Hcl31$146
Duloxetine Hcl16$128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$1,832$21,86924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →